Versant Venture Capital VI, L.P.

Versant Venture Capital VI divests 224,974 shares (22.7% of holdings) at blended $46.01 in 6 separate sales on 2025-09-30.

Versant Venture Capital VI, a 10% owner of LENZ, executed 6 separate sales on 2025-09-30 totaling 224,974 shares for $10,352,017.44 at prices ranging from $45.35 to $47.01, reducing holdings from 989,101 to 764,127 shares (a -22.7% net reduction). The company is unprofitable with net income of $-14,912,000.00 on revenue of $5,000,000.00, operating at a significant loss. The selling occurred amid a 30-day rally of +23.1% and near the 52-week high of $49.05, placing the current price $48.32 at -1.5% from peak. Five prior sales by the same insider at this ticker occurred on 2025-09-18 (12 days before this filing), all with outcomes not yet measurable. The scale of this divestiture—reducing a major stakeholder's position by roughly one-fifth—combined with the losses at the operating level and the timing near all-time highs, warrants attention to the company's cash runway and capital structure.

10% owner Versant Venture Capital VI fully exits LVTX: 2,903,403 shares sold for $4,068,828.97 at $1.40/share on 2025-09-19.

Versant Venture Capital VI, a 10% owner of LAVA Therapeutics, executed a complete exit from its position via 2 separate sales totaling 2,903,403 shares for $4,068,828.97 at $1.40 per share on 2025-09-19, reducing holdings from 2,903,403 shares to 0 shares (-100.0%). This liquidation occurs while the stock trades at $1.58, 22.6% below its 52-week high of $2.04, and follows a pattern of 5 prior sales at LVTX within the preceding 3 days (2025-09-16 through 2025-09-18). The company remains unprofitable with net income of $-8,639,000.00 against quarterly revenue of $6,992,000.00, though it has posted annual revenue growth of +77.0%. The complete exit by a major strategic shareholder during a period of consecutive daily sales suggests a systematic unwinding of the position and may signal reduced confidence in the near-term trajectory, particularly given the biotech's loss-making status.

Versant VC VI sells 135.3K shares (13.6% of holdings) at $42.23 avg; LENZ unprofitable with $-14.9M net income

Versant Venture Capital VI, L.P., a 10% owner of LENZ, executed 6 separate sales totaling 135,304 shares for $5,714,356.00 on 2025-09-18 at a blended average price of $42.23, reducing holdings from 991.5K to 856.2K shares. The current price of $41.26 sits 2.4% below the 52-week high of $42.27, and the stock has appreciated 38.6% over 90 days and 3.2% over 30 days. The company remains unprofitable with net income of $-14.9M in its most recent full fiscal year and a latest-quarter revenue of only $5.0M. The timing context shows 5 prior LENZ-specific sells by this insider all executed on 2025-08-25 and 2025-08-26, suggesting a concentrated liquidation pattern rather than isolated portfolio adjustment. With no measurable outcomes yet from the recent August trades, the sustained selling activity by a major VC shareholder warrants monitoring alongside the company's negative profitability profile.

VC fund Versant VI exits 1.68M LVTX shares (76.0% of holdings) in 3 days for $2.5M; company unprofitable, near 52-week low

Versant Venture Capital VI, L.P., a 10% owner of LAVA Therapeutics, conducted 6 separate sales totaling 1,684,434 shares for $2,502,260.76 across September 16–18, 2025, reducing its stake from 2,217,304 shares to 532,870 shares. The blended average sale price of $1.49 is near the current price of $1.47, and the exit occurred within a compressed 3-day window. Against this, LAVA is unprofitable (net income of $-8,639,000 in the latest quarter, negative full-year net income) and the stock sits at -27.9% from its 52-week high of $2.04. While the company has posted strong annual revenue growth of +77.0%, the combination of losses, proximity to 52-week lows, and a major VC fund's -76.0% reduction in holdings suggests diminishing conviction among insiders, particularly given the timing near recent lows and the magnitude of the exit relative to the insider's original position.

Versant Venture Capital VI sells 188,094 shares ($7.4M) across 3 days; VC holder retains 900,807 shares post-transaction.

Versant Venture Capital VI, the 10% owner of LENZ Therapeutics, executed 12 separate sales totaling 188.1K shares for $7.4M between August 22 and August 26, 2025, at prices ranging from $38.97 to $40.59 (blended average $39.47). This represents a 17.3% reduction in the VC firm's stake, though it retains 900.8K shares (approximately 81.7% of its prior holdings). The sales occurred as LENZ stock was near its 52-week high of $40.91 and have remained 5.6% above that level on a current-price basis. Notably, LENZ is unprofitable (negative $14.9M net income in the latest period) with only $5.0M quarterly revenue, yet the company has delivered a 22.2% 30-day gain and 34.6% 90-day gain. The timing pattern at this ticker is unproven—four of Versant's five prior LENZ trades occurred within the past 11 days, and none of the measurable prior sales have demonstrated well-timed execution at the 90-day mark. The concentrated selling over a three-day window at elevated price levels warrants investor attention regarding whether the VC firm views current valuations as optimized or whether secondary market liquidity was the primary driver.

Major VC investor Versant Venture Capital VI sold 260,713 shares (260.7K) for $10.3M at $39.34 avg, reducing stake 21.3%

Versant Venture Capital VI, a 10% owner of LENZ Therapeutics, executed 4 separate sales totaling 260,713 shares for $10,255,243.56 on August 15–18, 2025, at a blended average price of $39.34. This represents a 21.3% reduction in the investor's holding, from 1,223,591 shares pre-transaction to 962,878 shares post-transaction. The sales occurred near the stock's 52-week high of $40.91, with the current price now at $37.61. Notably, LENZ remains unprofitable (latest quarter net income: $-14,912,000.00) despite strong recent momentum (30-day and 90-day gains of +11.5% and +33.6% respectively). The timing of this substantial VC liquidation—while the stock remains elevated but the company's financial fundamentals show sustained losses—warrants attention as a potential signal of capital redeployment at a valuation inflection point.

10% owner Versant Venture Capital VI sold 191.4K shares at $34.00 for $6.5M; post-transaction holdings 1.58M shares; LENZ unprofitable ($-14.6M net income).

Versant Venture Capital VI, a 10% owner, executed a $6.5M sale on 2025-07-10, reducing its stake by 191,376 shares. The seller's cross-ticker track record shows 13 prior open-market sells with a 90d well-timed rate of 62.50%, indicating moderate success at selling before declines elsewhere. However, at LENZ specifically, prior transaction outcomes remain unmeasured (most recent same-ticker sales on 2025-06-10, 2025-06-18, 2025-06-20, and 2025-06-27 lack sufficient outcome data). The company remains unprofitable with a full-year net income of $-14.6M, and the stock has appreciated +16.3% over the trailing 30 days and +41.2% over 90 days, now trading -9.7% from its 52-week high of $37.37. The pattern of recurring sales at LENZ over a concentrated two-week window (four sales between 2025-06-10 and 2025-06-27, followed by this sale on 2025-07-10) warrants monitoring for directional conviction or liquidity needs.

10% Owner Versant VC VI sells 200,000 shares at $30.46; 4 sales in 8 days as stock holds +17.8% in 90 days vs $-14.6M net loss.

Versant Venture Capital VI divested 200,000 shares (10.2% of pre-transaction holdings) at $30.46 on 2025-06-27, the fourth sale executed in an 8-day window (2025-06-10 through 2025-06-27). This concentrated selling pattern occurs while the company reported a $-14,619,000.00 full-year net loss and remains unprofitable. The timing context is mixed: the stock currently trades at $30.05 (2.9% above the 30-day price and 17.8% above the 90-day price), suggesting the sales have not yet preceded a measurable decline. Across the insider's broader cross-ticker history, sells have been well-timed 62.50% of the time with an average 90-day return of -6.8%, but at this specific ticker (LENZ), the 4 prior measurable sales all lack yet-determined outcomes. The rapid succession of dispositions by a significant shareholder warrants investor attention given the company's unprofitable status and the clustering of exits.

10% owner Versant VC VI sells 334,801 shares for $10.1M at blended $30.19 across three trades, reducing stake by 14.5%

Versant Venture Capital VI, L.P., a 10% owner of LENZ, executed three separate sales totaling 334,801 shares for $10,107,817.95 ($10.1M) at an average price of $30.19 between June 18–20, 2025. This reduces the insider's position from 2,302,076 shares to 1,967,275 shares, a 14.5% reduction. The transaction occurred as LENZ stock traded near its 52-week high ($37.37), with the current price at $29.94 only 0.8% below the blended sale price. LENZ is unprofitable with net income of $-14,619,000.00 across the most recent full fiscal year, which provides context for evaluating the business condition at the time of the insider's sale. The insider's cross-ticker track record shows 9 prior open-market sells with a 62.50% well-timed rate (average 90-day return of -6.8%), though no prior trades at LENZ are yet measurable at the 90-day mark.

Versant Venture Capital VI sold 350,000 shares (21.9% of holdings) at $29.00; unprofitable LENZ trades at $29.58, down 20.8% from 52-week high.

Versant Venture Capital VI, a 10% owner, reduced its position in LENZ by 350,000 shares (from 1,598,789 to 1,248,789 shares) at $29.00 on 2025-06-10, raising $10.2M. The sale occurred while the stock is down 20.8% from its 52-week high of $37.37, though it has gained 2.1% over 30 days and 16.2% over 90 days. The seller's cross-ticker track record shows a 90-day well-timed rate of 62.50% with an average 90-day return of -6.8%, indicating modest timing discipline across other holdings. LENZ remains unprofitable with a net loss of $14.6M over its most recent full fiscal year, though market cap stands at $832.6M. The transaction reduces a significant institutional stake and warrants investor attention to whether the partial exit reflects confidence thresholds or liquidity allocation decisions at an unprofitable biotech.